Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.QPS has signed an agreement to acquire Bio-Kinetic Clinical Applications,an early clinical research organization with a 240-bed Phase I facility. The acquisition is subject to satisfaction of certain customary conditions to closing and is expected to close January 1, 2008.
Subscribe to our email newsletter
The pharmaceutical and biotechnology industries will now have access to dedicated, focused scientific expertise in the drug development spectrum from discovery and preclinical through IND into Phase I research.
The acquisition is being structured as a merger, with Bio-Kinetic shareholders receiving membership interests in QPS Holdings. Private equity firms Argentum Capital Partners and First Analysis, which led the recapitalization of Bio-Kinetic in 2005, will become equity holders of QPS along with Bio-Kinetic’s two founders.
Dale Bourg, CEO of Bio-Kinetic, said: “The acquisition of Bio-Kinetic will provide our clients with access to industry experts in LC/MS/MS, ELISA, biomarkers and genotyping—complex procedures that can provide immense value in the decision-making process while developing a compound.”